MADRIGAL PHARMACEUTICALS, INC. (MDGL) Form 8-K — Jul 30, 2026

$MDGLForm 8-KItems 2.02, 9.01Filed Jul 30, 2026, 7:03 AM ET0001628280-26-050775Original filing

Madrigal Pharmaceuticals reported second-quarter 2026 net sales of $364.3 million, representing 71% year-over-year growth driven by strong demand for Rezdiffra. The company surpassed 50,000 active patients recently and achieved nearly $1.3 billion in trailing-twelve-month net sales. Operationally, Madrigal advanced its pipeline by initiating Phase 1 dosing for MGL-2086, an oral GLP-1 receptor agonist intended for combination therapy with Rezdiffra. Additionally, the company strengthened its intellectual property portfolio with the issuance of three new patents covering dosing regimens and treatment for compensated cirrhosis.

Key figures

Revenue: 364.3
Revenue Yoy: 71%
Cash Position: 838.9
Ttm Sales: nearly $1.3 billion
One Time BDExpense: $25.0 million
Operating Expenses: $420.6 million
Patients On Therapy: >49,000

Price after filing

1 day: +1.5%7 days: -5.3%30 days: -0.9%

Close on the filing date to close N calendar days later (from $538.80). Historical, not a forecast.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.